Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Buy
56
LAB Quote, Financials, Valuation and Earnings
Last price:
$2.00
Seasonality move
:
15.27%
Day range:
$1.90 - $2.05
52-week range:
$1.21 - $3.04
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.58x
P/B ratio:
1.52x
Volume:
4.7M
Avg. volume:
1.9M
1-year change:
3.63%
Market cap:
$744.5M
Revenue:
$106.3M
EPS (TTM):
-$0.71
Analysts' Opinion
-
Consensus RatingStandard BioTools has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Standard BioTools has an estimated upside of 54.17% from its current price of $2.00.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $2.00.
Fair Value
-
According to the consensus of 0 analysts, Standard BioTools has 54.17% upside to fair value with a price target of -- per share.
LAB vs. S&P 500
-
Over the past 5 trading days, Standard BioTools has overperformed the S&P 500 by 6.84% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Standard BioTools does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Standard BioTools has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Standard BioTools reported revenues of $45M.
Earnings Growth
-
Standard BioTools has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Standard BioTools reported earnings per share of -$0.07.
Enterprise value:
433.4M
EV / Invested capital:
0.80x
Price / LTM sales:
3.58x
EV / EBIT:
--
EV / Revenue:
2.78x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.92x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$75.7M
Return On Assets:
-22.01%
Net Income Margin (TTM):
-79.92%
Return On Equity:
-48.03%
Return On Invested Capital:
-39.17%
Operating Margin:
-54.03%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $109.2M | $105.2M | $155.9M | $25.4M | $45M | |
| Gross Profit | $46.1M | $48.2M | $75.7M | $11.2M | $23.3M | |
| Operating Income | -$102.6M | -$64.6M | -$119.9M | -$17.5M | -$24.3M | |
| EBITDA | -$162.9M | -$52.8M | -$109.7M | -$13.5M | -$20.4M | |
| Diluted EPS | -$2.30 | -$0.96 | -$0.71 | -$0.27 | -$0.07 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $122.7M | $73.5M | $229M | $170.7M | $453.6M | |
| Total Assets | $323M | $282.2M | $414.9M | $339.3M | $681.5M | |
| Current Liabilities | $42.8M | $47.3M | $46.2M | $51.8M | $120.6M | |
| Total Liabilities | $171M | $182.9M | $477.7M | $471M | $192.2M | |
| Total Equity | $152M | $99.3M | -$62.7M | -$131.7M | $489.3M | |
| Total Debt | $54.1M | $64M | $64.7M | $64.6M | $55.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$77.2M | -$48.4M | -$143.5M | -$11.4M | -$27.9M | |
| Cash From Investing | -$129.5M | $73.6M | $324.3M | -$49.9M | -$30.9M | |
| Cash From Financing | $238.3M | -$6.1M | -$49.1M | -$1.2M | -$2K | |
| Free Cash Flow | -$80.7M | -$51.9M | -$148.5M | -$12.3M | -$30.1M | |
LAB
Sector
Market Cap
$744.5M
$44.6M
Price % of 52-Week High
65.79%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
5.94%
-0.68%
1-Year Price Total Return
3.63%
-29.09%
Beta (5-Year)
1.606
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$2.01
200-day SMA
Sell
Level
$2.14
Bollinger Bands (100)
Buy
Level
1.7 - 2.06
Chaikin Money Flow
Sell
Level
-107.3M
20-day SMA
Buy
Level
$1.89
Relative Strength Index (RSI14)
Buy
Level
54.24
ADX Line
Sell
Level
8.69
Williams %R
Neutral
Level
-48.0769
50-day SMA
Buy
Level
$1.87
MACD (12, 26)
Buy
Level
0.06
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Neutral
Level
297.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.3115)
Sell
CA Score
(Annual)
Level (-5.0015)
Buy
Beneish M-Score
(Annual)
Level (-2.9505)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (8.2782)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Stock Forecast FAQ
In the current month, LAB has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The LAB average analyst price target in the past 3 months is --.
-
Where Will Standard BioTools Stock Be In 1 Year?
According to analysts, the consensus estimate is that Standard BioTools share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Standard BioTools?
Analysts are divided on their view about Standard BioTools share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Standard BioTools is a Sell and believe this share price will drop from its current level to --.
-
What Is Standard BioTools's Price Target?
The price target for Standard BioTools over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is LAB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Standard BioTools is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LAB?
You can purchase shares of Standard BioTools via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Standard BioTools shares.
-
What Is The Standard BioTools Share Price Today?
Standard BioTools was last trading at $2.00 per share. This represents the most recent stock quote for Standard BioTools. Yesterday, Standard BioTools closed at $2.00 per share.
-
How To Buy Standard BioTools Stock Online?
In order to purchase Standard BioTools stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
